Want to see SPRY full AI Analyst Report?
Total Valuation
ARS Pharmaceuticals has a market cap or net worth of $850.04M. The enterprise value is $1.06B.
Market Cap$850.04M
Enterprise Value$1.06B
Share Statistics
ARS Pharmaceuticals has 99,303,260 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding99,303,260
Owned by Insiders59.91%
Owned by Institutions11.65%
Financial Efficiency
ARS Pharmaceuticals’s return on equity (ROE) is -1.50 and return on invested capital (ROIC) is -62.17%.
Return on Equity (ROE)-1.50
Return on Assets (ROA)-0.52
Return on Invested Capital (ROIC)-62.17%
Return on Capital Employed (ROCE)-0.62
Revenue Per Employee543.73K
Profits Per Employee-1.11M
Employee Count155
Asset Turnover0.26
Inventory Turnover2.44
Valuation Ratios
The current PE Ratio of ARS Pharmaceuticals is ―. ARS Pharmaceuticals’s PEG ratio is 0.00303.
PE Ratio―
PS Ratio13.63
PB Ratio10.05
Price to Fair Value10.05
Price to FCF-6.71
Price to Operating Cash Flow-4.86
PEG Ratio0.00303
Income Statement
In the last 12 months, ARS Pharmaceuticals had revenue of 84.28M and earned -171.30M in profits. Earnings per share was -1.74.
Revenue84.28M
Gross Profit63.85M
Operating Income-179.45M
Pretax Income-171.38M
Net Income-171.30M
EBITDA-167.41M
Earnings Per Share (EPS)-1.74
Cash Flow
In the last 12 months, operating cash flow was -175.07M and capital expenditures -248.00K, giving a free cash flow of -175.32M billion.
Operating Cash Flow-175.07M
Free Cash Flow-175.32M
Free Cash Flow per Share-1.77
Dividends & Yields
ARS Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.38
52-Week Price Change-49.91%
50-Day Moving Average8.72
200-Day Moving Average9.32
Relative Strength Index (RSI)46.64
Average Volume (3m)1.64M
Important Dates
ARS Pharmaceuticals upcoming earnings date is Aug 12, 2026, After Close (Confirmed).
Last Earnings DateMay 15, 2026
Next Earnings DateAug 12, 2026
Ex-Dividend Date―
Financial Position
ARS Pharmaceuticals as a current ratio of 7.28, with Debt / Equity ratio of 157.44%
Current Ratio7.28
Quick Ratio7.06
Debt to Market Cap0.08
Net Debt to EBITDA-0.33
Interest Coverage Ratio-69.05
Taxes
In the past 12 months, ARS Pharmaceuticals has paid -80.00K in taxes.
Income Tax-80.00K
Effective Tax Rate<0.01
Enterprise Valuation
ARS Pharmaceuticals EV to EBITDA ratio is -7.19, with an EV/FCF ratio of -7.03.
EV to Sales14.28
EV to EBITDA-7.19
EV to Free Cash Flow-7.03
EV to Operating Cash Flow-7.04
Balance Sheet
ARS Pharmaceuticals has $200.97M in cash and marketable securities with $96.52M in debt, giving a net cash position of $104.45M billion.
Cash & Marketable Securities$200.97M
Total Debt$96.52M
Net Cash$104.45M
Net Cash Per Share$1.05
Tangible Book Value Per Share$1.01
Margins
Gross margin is 77.10%, with operating margin of -212.92%, and net profit margin of -203.25%.
Gross Margin77.10%
Operating Margin-212.92%
Pretax Margin-203.35%
Net Profit Margin-203.25%
EBITDA Margin-198.64%
EBIT Margin-200.26%
Analyst Forecast
The average price target for ARS Pharmaceuticals is $28.33, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$28.33
Price Target Upside241.37% Upside
Analyst ConsensusStrong Buy
Analyst Count4
Revenue Growth Forecast1.92%
EPS Growth Forecast-1130.30%